Join

Compare · OCDX vs QTNT

OCDX vs QTNT

Side-by-side comparison of Ortho Clinical Diagnostics Holdings plc (OCDX) and Quotient Limited (QTNT): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both OCDX and QTNT operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
  • OCDX is the larger of the two at $4.08B, about 26.1x QTNT ($156.5M).
  • OCDX has more recent analyst coverage (8 ratings vs 2 for QTNT).
MetricOCDXQTNT
Company
Ortho Clinical Diagnostics Holdings plc
Quotient Limited
Price
$17.64+0.46%
$0.40+10.10%
Market cap
$4.08B
$156.5M
1M return
-
-
1Y return
-
-
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Exchange
NASDAQ
NASDAQ
IPO
2021
2014
News (4w)
0
0
Recent ratings
8
2
OCDX

Ortho Clinical Diagnostics Holdings plc

Ortho Clinical Diagnostics Holdings plc engages in the vitro diagnostics business worldwide. The company offers automated instruments; and assays, reagents, and other consumables that are used by these instruments to generate test results. Its solutions include clinical chemistry and immunoassay instruments and tests to detect and monitor disease progression across a spectrum of therapeutic areas, including COVID-19 antibody and antigen tests; and immunohematology instruments and tests for blood typing to ensure patient-donor compatibility in blood transfusions, as well as donor screening instruments and tests for blood and plasma screening for infectious diseases. The company also engages in contract manufacturing activities; and provides orthocare services. Its products are used in hospitals, laboratories, clinics, blood banks, and donor centers. The company was founded in 1939 and is headquartered in Raritan, New Jersey.

QTNT

Quotient Limited

Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, commercializes, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally. The company is developing MosaiQ, a proprietary technology platform, which provides tests for immunohematology, serological disease screening, and molecular disease screening. Its conventional reagent products for blood grouping include antisera products that are used to identify blood group antigens; reagent red blood cells, which enable the identification of blood group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping. The company also offers MosaiQ COVID-19 Microarray that is designed as a serological disease screening microarray specific to COVID-19 antibody detection. It sells its products to hospitals, donor collection agencies, independent testing laboratories, original equipment manufacturers, and blood banking operation and other diagnostics companies. Quotient Limited was founded in 2007 and is headquartered in Eysins, Switzerland.

Latest OCDX

Latest QTNT